Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL

NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

PRNewsWire • Dec 12, 2025

Are Investors Undervaluing Alkermes (ALKS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Dec 8, 2025

Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 6, 2025

Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Nov 27, 2025

Alkermes to Participate in Two Upcoming Investor Conferences

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 8th Annual Evercore Healthcare Conference Date/Time: Wednesday, Dec. 3, 2025 at 2:10 p.m. ET (7:10 p.m. GMT) Piper Sandler 37th Annual Healthcare Conference Date/Time: Thursday, Dec. 4, 2025 at 12:00 p.m. ET (5:00 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alke.

Business Wire • Nov 25, 2025

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal

Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.

Zacks Investment Research • Nov 20, 2025

Alkermes Ups Its Avadel Bid To $2.37 Billion In A Buyout Battle With Lundbeck

Alkermes upped its bid on Avadel to $2.37 billion on Wednesday, coming in with the "superior proposal" vs. Lundbeck's unexpected pitch.

Investors Business Daily • Nov 19, 2025

Alkermes raises offer for Avadel after Lundbeck bid

Alkermes said on Wednesday it has sweetened its offer to buy Avadel Pharmaceuticals , beating a rival bid from Denmark's Lundbeck and valuing the sleep disorder drugmaker at up to $2.37 billion.

Reuters • Nov 19, 2025

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended offer under which Alkermes will acquire Avadel (the "Acquisition") for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash and one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional cash payment of $1.50 per share, contingent upon final U.S. Food and Drug Administration ("FDA") LUMRYZ™ Approval (as defined in the form of CVR agreement to be entered into by Alkermes and the rights agent) for the treatment of idiopathic hypersomnia in adults by the end of 2028 (the "Increased Offer"). In connection with the Increased Offer, Alkermes and Avadel have entered into an amendment, dated November 18, 2025 (the "Amendment"), to the definitive transaction agreement between the parties (the "Transaction Agreement" and, as amended, the "Amended Agreement") previously entered into and announced on October 22, 2025 (the "October 2.7 Announcement").

PRNewsWire • Nov 19, 2025

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

Top-ranked stocks TakeTwo Interactive Software (TTWO), Allstate (ALL), SoFi Technologies (SOFI), Alkermes (ALKS) and Morgan Stanley (MS) are likely to beat on the bottom line in their upcoming releases.

Zacks Investment Research • Nov 19, 2025